A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Status
- RECRUITING
- Phase
- NA
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- Status
- WITHDRAWN
- Phase
- PHASE2
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
- Status
- RECRUITING
- Phase
- N/A
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
- Status
- COMPLETED
- Phase
- N/A
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- Status
- RECRUITING
- Phase
- N/A
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
- Status
- TERMINATED
- Phase
- N/A
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
PD-L1 Expression in Cancer (PECan Study).
- Status
- UNKNOWN
- Phase
- NA
Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment
- Status
- COMPLETED
- Phase
- N/A
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant T-VEC in High Risk Early Melanoma
- Status
- SUSPENDED
- Phase
- PHASE2
Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
- Status
- COMPLETED
- Phase
- NA